ResultsIQ

ResultsIQ › Latest results › Anuh Pharma Limited

Anuh Pharma Limited Q3 FY26 results deck summary

NSE: ANUHPHR · BSE: 506260

Results deck of 13 Feb 2026, summarised by AI from the filing.

Q3 FY26 revenue ₹197.18 cr with EBITDA ₹20.91 cr and margin 10.60%; USFDA inspection completed with zero Form 483 observations.

Key takeaways

  1. Q3 FY26 revenue Operating revenue ₹197.18 cr (Q2 FY26: ₹185.88 cr, +6.08% QoQ); EBITDA ₹20.91 cr (Q2 FY26: ₹12.86 cr, +62.63% QoQ).
  2. Growth guidance The company anticipates a steady growth rate of 15-16% per annum.
  3. Margin expansion Operating margin improved to 23.28% from 22.24% in the preceding quarter, driven by enhanced capacity utilization.
  4. USFDA inspection The Company completed the USFDA inspection conducted in February 2026 with zero Form 483 observations.
  5. 9M FY26 EBITDA 9M FY26 EBITDA stood at ₹47.45 cr versus ₹50.29 cr in the previous year, with margins moderating during the period.

Original filing on BSE

Anuh Pharma Limited Q1 FY27 results

As filed: Revenue ₹194 cr (+4% year on year), EBITDA ₹16.3 cr (+48% year on year), PAT ₹11.4 cr (+43% year on year), EBITDA margin 8.4% (+249 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹202 cr (+2% year on year), EBITDA ₹19.9 cr (+5% year on year), PAT ₹11.7 cr (−3% year on year), EBITDA margin 9.8% (+24 bps). Score 35 of 100, Below trend. EBITDA margin rose 24 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: −4.4% in 30 days (Nifty 500: +2.5%).
  • Q3 FY26: Revenue ₹197 cr (+23% year on year), EBITDA ₹16.8 cr (+20% year on year), PAT ₹13.5 cr (+35% year on year), EBITDA margin 8.5% (−23 bps). Score 68 of 100, Above trend. EBITDA margin fell 23 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.1% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹186 cr, EBITDA ₹12.0 cr, PAT ₹8.0 cr, EBITDA margin 6.5%. Not scored. No result for the same quarter last year. Share price after the results: −4.3% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹186 cr, EBITDA ₹11.0 cr, PAT ₹8.0 cr, EBITDA margin 5.9%. Not scored. No result for the same quarter last year. Share price after the results: −7.0% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹198 cr, EBITDA ₹19.0 cr, PAT ₹12.0 cr, EBITDA margin 9.6%. Not scored. No result for the same quarter last year. Share price after the results: −0.4% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹160 cr, EBITDA ₹14.0 cr, PAT ₹10.0 cr, EBITDA margin 8.8%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Anuh Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.